Milica Bozic1, Angels Betriu1, Marcelino Bermudez-Lopez1, Alberto Ortiz2, Elvira Fernandez3, Jose M Valdivielso3. 1. Vascular and Renal Translational Research Group, Institut de Recerca Biomedica de Lleida, Lleida, Spain; and. 2. Instituto de Investigacion Sanitaria Fundación Jiménez Díaz, Autonomous University of Madrid, Red de Investigación Renal del Instituto de Salud Carlos III, Madrid, Spain. 3. Vascular and Renal Translational Research Group, Institut de Recerca Biomedica de Lleida, Lleida, Spain; and valdivielso@medicina.udl.es efernandez@irblleida.cat.
Abstract
BACKGROUND AND OBJECTIVES: Atherosclerosis is highly prevalent in CKD. The rate of progression of atherosclerosis is associated with cardiovascular events. Fibroblast growth factor 2 (FGF-2) is a member of the FGF family with potentially both protective and deleterious effects in the development of atherosclerosis. The role of circulating FGF-2 levels in the progression of atherosclerosis in CKD is unknown. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We used a multicenter, prospective, observational cohorts study of 481 patients with CKD. We determined the presence of atheroma plaque in ten arterial territories by carotid and femoral ultrasounds. Progression of atheromatosis was defined as an increase in the number of territories with plaque after 24 months. Plasma levels of FGF-2 were measured by multiplex analysis. A multivariable logistic regression analysis was performed to determine whether plasma FGF-2 levels were associated with atheromatosis progression. RESULTS: Average age of the population was 61 years. The percentage of patients in each CKD stage was 51% in stage 3, 41% in stages 4-5, and 8% in dialysis. A total of 335 patients (70%) showed plaque at baseline. Atheromatosis progressed in 289 patients (67%). FGF-2 levels were similar between patients with or without plaque at baseline (79 versus 88 pg/ml), but lower in patients with atheromatosis progression after 2 years (78 versus 98 pg/ml; P<0.01). In adjusted analyses, higher plasma FGF-2 was associated with lower risk of atheromatosis progression (odds ratio [OR], 0.86; 95% confidence interval [95% CI], 0.76 to 0.96; per 50 pg/ml increment). Analysis of FGF-2 in tertiles showed that atheroma progression was observed for 102 participants in the lowest tertile of FGF-2 (reference group), 86 participants in the middle tertile of FGF-2 (adjusted OR, 0.70; 95% CI, 0.40 to 1.20), and 74 participants in the lowest tertile of FGF-2 (adjusted OR, 0.48; 95% CI, 0.28 to 0.82). CONCLUSIONS: Low FGF-2 levels are independently associated with atheromatosis progression in CKD.
BACKGROUND AND OBJECTIVES:Atherosclerosis is highly prevalent in CKD. The rate of progression of atherosclerosis is associated with cardiovascular events. Fibroblast growth factor 2 (FGF-2) is a member of the FGF family with potentially both protective and deleterious effects in the development of atherosclerosis. The role of circulating FGF-2 levels in the progression of atherosclerosis in CKD is unknown. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We used a multicenter, prospective, observational cohorts study of 481 patients with CKD. We determined the presence of atheroma plaque in ten arterial territories by carotid and femoral ultrasounds. Progression of atheromatosis was defined as an increase in the number of territories with plaque after 24 months. Plasma levels of FGF-2 were measured by multiplex analysis. A multivariable logistic regression analysis was performed to determine whether plasma FGF-2 levels were associated with atheromatosis progression. RESULTS: Average age of the population was 61 years. The percentage of patients in each CKD stage was 51% in stage 3, 41% in stages 4-5, and 8% in dialysis. A total of 335 patients (70%) showed plaque at baseline. Atheromatosis progressed in 289 patients (67%). FGF-2 levels were similar between patients with or without plaque at baseline (79 versus 88 pg/ml), but lower in patients with atheromatosis progression after 2 years (78 versus 98 pg/ml; P<0.01). In adjusted analyses, higher plasma FGF-2 was associated with lower risk of atheromatosis progression (odds ratio [OR], 0.86; 95% confidence interval [95% CI], 0.76 to 0.96; per 50 pg/ml increment). Analysis of FGF-2 in tertiles showed that atheroma progression was observed for 102 participants in the lowest tertile of FGF-2 (reference group), 86 participants in the middle tertile of FGF-2 (adjusted OR, 0.70; 95% CI, 0.40 to 1.20), and 74 participants in the lowest tertile of FGF-2 (adjusted OR, 0.48; 95% CI, 0.28 to 0.82). CONCLUSIONS: Low FGF-2 levels are independently associated with atheromatosis progression in CKD.
Authors: Robert J Lederman; Farrell O Mendelsohn; R David Anderson; Jorge F Saucedo; Alan N Tenaglia; James B Hermiller; William B Hillegass; Krishna Rocha-Singh; Thomas E Moon; M J Whitehouse; Brian H Annex Journal: Lancet Date: 2002-06-15 Impact factor: 79.321
Authors: P-J Touboul; M G Hennerici; S Meairs; H Adams; P Amarenco; M Desvarieux; S Ebrahim; M Fatar; R Hernandez Hernandez; S Kownator; P Prati; T Rundek; A Taylor; N Bornstein; L Csiba; E Vicaut; K S Woo; F Zannad Journal: Cerebrovasc Dis Date: 2004-11-02 Impact factor: 2.762
Authors: Valvanera Fernández-Laso; Nerea Méndez-Barbero; Jose M Valdivielso; Angels Betriu; Elvira Fernández; Jesús Egido; Jose L Martín-Ventura; Luis M Blanco-Colio Journal: Atherosclerosis Date: 2017-03-31 Impact factor: 5.162
Authors: Lidia Anguiano; Marta Riera; Julio Pascual; José Manuel Valdivielso; Clara Barrios; Angels Betriu; Sergi Clotet; Sergi Mojal; Elvira Fernández; María José Soler Journal: Atherosclerosis Date: 2016-08-24 Impact factor: 5.162
Authors: Milica Bozic; Ángeles Álvarez; Carmen de Pablo; Maria-Dolores Sanchez-Niño; Alberto Ortiz; Xavier Dolcet; Mario Encinas; Elvira Fernandez; José Manuel Valdivielso Journal: PLoS One Date: 2015-08-31 Impact factor: 3.240
Authors: Andy W C Man; Min Chen; Zhixiong Wu; Gisela Reifenberg; Andreas Daiber; Thomas Münzel; Ning Xia; Huige Li Journal: Front Pharmacol Date: 2020-04-29 Impact factor: 5.810